COVID-19 (Coronavirus) Discharge Instructions after Monoclonal Antibody Infusion
After treatment of COVID-19 with casirivimab-imdevimab, continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing).
Casirivimab-imdevimab is not a vaccine and will not replace the COVID-19 vaccine. The COVID-19 vaccine provides long-term protection from COVID-19. If you are planning to receive the COVID-19 vaccine, wait for at least 90 days after the casirivimab-imdevimab infusion before being vaccinated. There is a theoretical risk that casirivimab-imdevimab may reduce your body's immune response to the COVID-19 vaccine if you receive them too close to each other.
Allergic reactions can happen during and after infusion of casirivimab-imdevimab. Tell your healthcare provider right away if you get any of the following signs and symptoms of allergic reactions:
- shortness of breath,
- low blood pressure,
- swelling of your lips, face, or throat,
- rash including hives, itching, muscle aches, and dizziness.
Side effects of getting the medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.
Tell your healthcare provider right away if you have any allergic reaction or side effect that bothers you or does not go away. Report side effects to FDA MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088, or call 1-844-734-6643.
This page is not specific to your child, but provides general information on the topic above. If you have any questions, please call your clinic. For more reading material about this and other health topics, please call or visit Children's Minnesota Family Resource Center library, or visit www.childrensmn.org/educationmaterials.
© 2021 Children's Minnesota